CX3CL1 and neoplasm: Although gene therapy involving the transfer of CX3CL1 to cancer cells was demonstrated to induce a robust anti-cancer effect (64–66), we did not see a significant reduction in tumour size following co-treatment with CX3CL1 and MTX in the therapeutic mouse model (Supplementary Figure S2).